GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

The Global Alcohol-Related Liver Disease Market report for 2025-2035 highlights the escalating trend of alcohol-related liver conditions like alcoholic fatty liver disease (AFLD), alcoholic hepatitis, ...

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

This study reveals that neutrophil extracellular traps (NETs) drive macrophage-derived chemokine production (CXCL9/10/11) to promote CD8+ T cell ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

Despite these antifibrotic treatments being available for a decade, mortality remains high, with an average survival time of only three to five years from diagnosis.

In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.